MEGACE Drug Patent Profile
✉ Email this page to a colleague
When do Megace patents expire, and what generic alternatives are available?
Megace is a drug marketed by Bristol Myers Squibb and Endo Pharms Inc and is included in three NDAs. There are five patents protecting this drug.
The generic ingredient in MEGACE is megestrol acetate. There are eighteen drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the megestrol acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Megace
A generic version of MEGACE was approved as megestrol acetate by STRIDES PHARMA on August 8th, 1988.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MEGACE?
- What are the global sales for MEGACE?
- What is Average Wholesale Price for MEGACE?
Summary for MEGACE
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 90 |
Clinical Trials: | 35 |
Patent Applications: | 4,421 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for MEGACE |
DailyMed Link: | MEGACE at DailyMed |
![MEGACE drug patent expirations Drug patent expirations by year for MEGACE](/p/graph/s/t/MEGACE-patent-expirations.png)
![Drug Prices for MEGACE](/p/graph/drug-price/MEGACE.png)
Recent Clinical Trials for MEGACE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
National Cancer Institute (NCI) | Phase 1/Phase 2 |
Ontario Institute for Cancer Research | Phase 1 |
Sunnybrook Health Sciences Centre | Phase 1 |
US Patents and Regulatory Information for MEGACE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bristol Myers Squibb | MEGACE | megestrol acetate | SUSPENSION;ORAL | 020264-001 | Sep 10, 1993 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Endo Pharms Inc | MEGACE ES | megestrol acetate | SUSPENSION;ORAL | 021778-001 | Jul 5, 2005 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Endo Pharms Inc | MEGACE ES | megestrol acetate | SUSPENSION;ORAL | 021778-001 | Jul 5, 2005 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Endo Pharms Inc | MEGACE ES | megestrol acetate | SUSPENSION;ORAL | 021778-001 | Jul 5, 2005 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Bristol Myers Squibb | MEGACE | megestrol acetate | TABLET;ORAL | 016979-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MEGACE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bristol Myers Squibb | MEGACE | megestrol acetate | SUSPENSION;ORAL | 020264-001 | Sep 10, 1993 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for MEGACE
See the table below for patents covering MEGACE around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Australia | 1828192 | ⤷ Sign Up | |
Slovakia | 281841 | ⤷ Sign Up | |
Slovakia | 185392 | COMPOUND WITH MEGESTROL-ACETATE | ⤷ Sign Up |
Denmark | 0519351 | ⤷ Sign Up | |
Finland | 922764 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |